EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Betahistine for residual dizziness after canalith repositioning in benign paroxysmal positional vertigo: a systematic review of randomized controlled trials

Esteban Ortiz-Prado, Jorge Vasconez-Gonzalez, Sandra Gavilanes-Rodriguez, Melissa Castillo-Bustamante, Valeria Barreto, Mónica Maya-Castro, Juan S Izquierdo-Condoy

Frontiers in Pharmacology · 02.06.2026 · 17

DOI: 10.3389/fphar.2026.1855843 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.06.2026. Verfasst von Esteban Ortiz-Prado und 6 weiteren Autor:innen. Beteiligte Einrichtung: One Health Research Group, Universidad de Las Americas, Quito, Ecuador. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Benign paroxysmal positional vertigo (BPPV) is the most common peripheral vestibular disorder. Although canalith repositioning maneuvers (CRMs) are highly effective, a substantial proportion of patients experience residual dizziness (RD) after successful repositioning. Betahistine has been proposed as an adjunctive therapy to facilitate recovery; however, its effectiveness in RD remains uncertain.

Aims

To evaluate the efficacy and safety of betahistine in adults with BPPV who experience residual dizziness after canalith repositioning maneuvers.

Methods

A systematic review was conducted in accordance with the PRISMA 2020 guidelines. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception to 1 February 2026. Randomized controlled trials including adults with BPPV who were treated with CRMs and presented with residual dizziness were eligible. Betahistine administered as adjunctive therapy was compared with placebo, no treatment, maneuver alone, or other pharmacological interventions. Two reviewers independently performed study selection, data extraction, and risk of bias assessment using the JBI checklist. Due to heterogeneity, findings were synthesized narratively.

Results

Four randomized controlled trials published between 2012 and 2022, including approximately 418 participants, were included. Betahistine daily doses ranged from 36 to 48 mg/day, with treatment durations of 1–4 weeks. Outcomes assessed included symptom intensity (VAS), disability (DHI), participation measures, duration of RD, and clinical resolution. Two trials reported significant improvements in symptom reduction, disability scores, or probability of RD resolution with betahistine, whereas two studies found no clear differences in primary outcomes or final clinical resolution compared with controls. Methodological quality varied, with one study considered at low risk of bias and three presenting uncertainties in key domains.

Conclusion

Betahistine may provide symptomatic or functional improvement in selected patients with residual dizziness after CRMs, but current randomized evidence remains limited, heterogeneous, and methodologically uncertain. Routine or universal use is not supported. Further adequately powered trials with standardized RD definitions, comparable outcomes, longer follow-up, and objective vestibular assessments are needed to clarify its clinical role. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261339853 .

Schlagwörter

Stichwörter der Autor:innen

benign paroxysmal positional vertigobetahistinecanalith repositioning maneuversrandomized controlled trialsresidual dizziness

Autor:innen und Institutionen

  • One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
  • Ear and Vertigo Clinic, Quito, Ecuador.
  • Universidad Pontificia Bolivariana, Vertigo and Dizziness Center in Medellín, Medellín, Colombia.
  • Postgraduate Program in Otolaryngology, Universidad Central Del Ecuador, Quito, Ecuador.
  • Department of Otolaryngology, Faculty of Medicine, Universidad de Las Americas, Quito, Ecuador.

Zitieren

APA

Ortiz-Prado, E., Vasconez-Gonzalez, J., Gavilanes-Rodriguez, S., Castillo-Bustamante, M., Barreto, V., Maya-Castro, M., & Izquierdo-Condoy, J. S. (2026). Betahistine for residual dizziness after canalith repositioning in benign paroxysmal positional vertigo: a systematic review of randomized controlled trials. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1855843

Vancouver

Ortiz-Prado E, Vasconez-Gonzalez J, Gavilanes-Rodriguez S, Castillo-Bustamante M, Barreto V, Maya-Castro M, et al. Betahistine for residual dizziness after canalith repositioning in benign paroxysmal positional vertigo: a systematic review of randomized controlled trials. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1855843

BibTeX
@article{OrtizPrado2026,
  author = {Ortiz-Prado, Esteban and Vasconez-Gonzalez, Jorge and Gavilanes-Rodriguez, Sandra and Castillo-Bustamante, Melissa and Barreto, Valeria and Maya-Castro, Mónica and Izquierdo-Condoy, Juan S},
  title = {Betahistine for residual dizziness after canalith repositioning in benign paroxysmal positional vertigo: a systematic review of randomized controlled trials},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1855843}
}
Kostenlos starten →